Candel Therapeutics Reports on Shareholder Vote Outcomes
Ticker: CADL · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1841387
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
TL;DR
Candel shareholders voted on key issues June 17th, results filed today.
AI Summary
Candel Therapeutics, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of its security holders on June 17, 2025. The filing details the outcome of these votes, which are crucial for the company's corporate governance and strategic direction.
Why It Matters
This filing provides transparency on key decisions made by Candel Therapeutics' shareholders, impacting the company's future operations and governance.
Risk Assessment
Risk Level: low — This is a routine filing reporting on shareholder votes, not indicating new financial or operational risks.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of earliest event reported
- June 18, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- Needham, Massachusetts (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Candel Therapeutics' security holders?
The filing indicates that matters were submitted to a vote of security holders on June 17, 2025, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 17, 2025.
What is Candel Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 117 Kendrick St Suite 450, Needham, Massachusetts 02494.
What is the Commission File Number for Candel Therapeutics, Inc.?
The Commission File Number for Candel Therapeutics, Inc. is 001-40629.
What is the IRS Employer Identification Number for Candel Therapeutics, Inc.?
The IRS Employer Identification Number for Candel Therapeutics, Inc. is 52-2214851.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding Candel Therapeutics, Inc. (CADL).